Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

The impulse at the root is ancient and admirable. In Jewish tradition: tikkun olam—literally, repair of the world. In its kabbalistic form, it described uncovering divine sparks hidden in ordinary ...

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...

Recursion Pharmaceuticals (RXRX) shares recently closed at US$3.98, with the stock showing a negative return over the past month and past 3 months, which may prompt investors to reassess its current ...

Imagine a computer program that doesn’t just do what it’s told, but actively looks at its own code, identifies weaknesses, and rewrites itself to be smarter. Then, with its newly increased ...

Earlier in January, Recursion Pharmaceuticals updated investors at the JP Morgan Healthcare Conference on its AI-powered drug discovery platform, clinical programs, and collaborations with partners ...

The book takes a close look at how knowledge spreads among people and throughout societies. For example: “The Emperor’s New Clothes.” In this Hans Christian Andersen story, con men tell a vain emperor ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...